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Background: In vivo imaging using genetic reporters is a central supporting tool in the development of cell and
gene therapies affording us the ability to selectively track the therapeutic indefinitely. Previous studies have
demonstrated the utility of the human norepinephrine transporter (hNET) as a positron emission tomography/single
photon emission computed tomography (PET/SPECT) genetic reporter for in vivo cellular imaging. Here, our aim
was to extend on this work and construct a tricistronic vector with dual optical (firefly luciferase) and nuclear (hNET)
in vivo imaging and ex vivo histochemical capabilities. Guiding this development, we describe how a fluorescent
substrate for hNET, 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP+), can be used to optimise vector design
and serve as an in vitro functional screen.
Methods: Vectors were designed to co-express a bright red-shifted firefly luciferase (FLuc), hNET and a small marker
gene RQR8. Genes were co-expressed using 2A peptide linkage, and vectors were transduced into a T cell line,
SupT1. Two vectors were constructed with different gene orientations; FLuc.2A.RQR8.2A.hNET and hNET.2A.FLuc.2A.
RQR8. hNET function was assessed using ASP+-guided flow cytometry. In vivo cellular conspicuity was confirmed
using sequential bioluminescence imaging (BLI) and SPECT imaging of transduced SupT1 cells injected into the
flanks of mice.
Results: SupT1/FLuc.2A.RQR8.2A.hNET cells resulted in >4-fold higher ASP+ uptake compared to SupT1/hNET.2A.
FLuc.2A.RQR8, suggesting that 2A orientation effected hNET function. SupT1/FLuc.2A.RQR8.2A.hNET cells were readily
visualised with both BLI and SPECT, demonstrating high signal to noise at 24 h post 123I-meta-iodobenzylguanidine
(MIBG) administration.
Conclusions: In this study, a pre-clinical tricistronic vector with flow cytometry, BLI, SPECT and histochemical
capabilities was constructed, which can be widely applied in cell tracking studies supporting the development
of cell therapies. The study further demonstrates that hNET function in engineered cells can be assessed using
ASP+-guided flow cytometry in place of costly radiosubstrate methodologies. This fluorogenic approach is
unique to the hNET PET/SPECT reporter and may prove valuable when screening large numbers of cell lines or
vector/mutant constructs.
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Cellular therapy with engineered cells is a promising
area and is finding increasing application in regenerative
medicine and cancer adoptive immunotherapy. In the
clinical setting, T cell-based studies using chimeric anti-
gen receptor (CAR) therapy have shown outstanding ef-
ficacy in refractory cancers [1-4]. More broadly, induced
progenitor cells have been shown to regenerate different
organs and systems in neurodegenerative [5], cardiovas-
cular [6,7] and musculoskeletal [8] disorders. These ther-
apeutics are different from standard therapies such as
small molecules or proteins: they are essentially living
therapies with no half-life, a complex engraftment and
multifaceted in vivo behaviour.
A key limitation of pre-clinical and clinical development
of advanced cellular therapies is lack of a satisfactory
method for tracking these cells over sufficiently long pe-
riods of time. Direct or transient labelling methods, such
as iron-labelled cells for magnetic resonance imaging
(MRI) or 111In-oxine-labelled cells for single photon emis-
sion computed tomography (SPECT) are unsuitable for
the time frame of immunotherapy studies. These allow
imaging over hours/days [9-14], which are insufficient to
study the complex biological integration and efficacy of
cellular therapies, which can evolve over many weeks and
months. A credible option is selective genetic modification
of cells with a marker gene, using an integrating vector, to
selectively track the cellular therapeutic indefinitely.
Several different approaches to genetic reporter im-
aging have been proposed [15,16]. As a translational ap-
proach, positron emission tomography (PET) or SPECT
show most promise. One such PET/SPECT genetic re-
porter is the human norepinephrine transporter (hNET)
[17]. In combination with radiolabelled noradrenaline ana-
logues, meta-iodobenzylguanidine (MIBG) or meta-
hydroxyephedrine (mHED), hNET engineered cells can be
mapped in vivo via SPECT (123I-MIBG) or PET (124I-
MIBG, 11C-mHED) [17-19]. It has been demonstrated that
the technique has quantitative capabilities and has been
used in longitudinal imaging studies of adoptively trans-
ferred T cells and gene therapy [20,21].
Here our aim was to construct a tricistronic vector co-
expressing hNET with firefly luciferase (FLuc) and a
compact suicide/marker gene, RQR8 [22]. This triple
construct extends upon the previously designed hNET-
eGFP bicistronic construct [18]. The hNET-FLuc con-
struct is a novel addition for in vivo bioluminescence
imaging (BLI), and the triple construct of hNET-FLuc-
RQR8 has potential for histochemistry and therapeutic
application. In this study, several vector constructs were
designed and tested. Screening for a lead construct, we
show that hNET function can be assessed in vitro using
ASP+, a fluorescent analogue of the neurotoxin MPP+
and hNET substrate [23,24], in place of conventionaland costly radiosubstrate methodologies. Using this ap-
proach, we determined the optimal gene orientation of
the tricistronic construct. Finally, we performed sequen-
tial BLI and 123I-MIBG SPECT in vivo imaging.Methods
Generation of tricistronic retroviral vectors and
transduction of SupT1 cells
All cell culture medium and supplements were ob-
tained from Lonza BioWhittaker (Walkersville, USA)
unless otherwise stated. A human T cell lymphoblastic
lymphoma-derived cell line (SupT1) was obtained from
the American Type Culture Collection (ATCC, Univer-
sity Boulevard Manassas, USA) and cultured in RPMI
1640 media (St. Louis, USA) supplemented with 10%
foetal bovine serum (FBS) and GlutaMAX (Gibco,
Grand Island, USA). Cell lines were maintained at 37°C
in a humidified 5% CO2 atmosphere. Three SupT1 cell
populations were engineered, each with a different ex-
pression cassette; (1) an IRES-based bisictronic vector
encoding for hNET and a cell surface marker CD34 (vec-
tor 1: SupT1/hNET.I.CD34), (2) a 2A peptide-linked tri-
cistronic vector encoding for hNET, red-shifted codon
optimised FLuc [25] and a highly compact marker/suicide
gene RQR8 [22] with 2A linkage at the N-terminus of
hNET (vector 2: SupT1/FLuc.2A.RQR8.2A.hNET) and (3)
at the C-terminus hNET (vector 3: SupT1/hNET.2A.
FLuc.2A.RQR8). Moloney murine leukaemia virus (Mo-
MuLV) long terminal repeat (LTR) promoter was used.
SupT1 cells were transduced with RD114 pseudotyped
supernatant generated from transfection of HEK-293T
cells with the expression plasmids supplying Gagpol (gift
from Elio Vanin, Baylor College of Medicine), RD114 en-
velope (gift from Mary Collins, University College
London) PeqPam-env and each of the three hNET encod-
ing vectors above. Transduction efficiency was determined
by flow cytometry with αCD34-APC staining for vector 1
and QBEnd10 staining as previously described [22] for
vectors 2 and 3.Optimisation of staining conditions for ASP+-guided flow
cytometry
SupT1 cells (1 × 106) transduced with hNET vector 1
were incubated at 37°C with varying concentrations of
ASP+ (1 × 10−3, 5 × 10−3, 1 × 10−2, 5 × 10−2, 0.1, 0.5, 1
μM) for 10, 30, 60, 120 and 240 min. The cells were
washed once with fluorescence activate cell sorting
(FACS) buffer containing 1% FBS, phosphate saline buf-
fer (PBS) and 50 mg/mL Normocin (InvivoGen, San
Diego, USA). The supernatant was discarded and cells
were re-suspended in 500 μL of FACS buffer. Flow cy-
tometry was performed using Beckman Coulter Cyan in-
strument (Beckman Coulter, Brea, USA).
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hNET expressing SupT1 cells
Optimal ASP+ staining conditions determined above
were used for ASP+-guided flow sorting of SupT1 cell
lines expressing the three hNET vector constructs.
Cells were prepared as described above. ASP+ mean
fluorescence intensities (MFI) were determined pre-
and post-FACS (Beckman Coulter MoFlo-XDP) using
areas under the curve and subtracting any non-specific
signal from non-transduced SupT1 (SupT1/NT) cell
populations. Measurements were acquired in tripli-
cates for each cell line and statistical significance of
differences between mean values was obtained with
IBM SPSS software using the one-way ANOVA and
the Tukey’s HSD test.In vitro radiotracer uptake assay
SupT1 cells expressing vectors 1 and 2 were further char-
acterised by radiosubstrate uptake studies. 1 × 106
SupT1/hNET.I.CD34, SupT1/FLuc.2A.RQR8.2A.hNET
and SupT1/NT cells were incubated for 30 min at 37°C
with [125I]-MIBG (7.4 kBq). The cells were rapidly
washed twice with 500 μL ice-cold PBS and the super-
natant collected. Cell pellets were resuspended in 1 mL
PBS. Radioactive uptake was determined by gamma
counting (WIZARD, PerkinElmer, Beaconsfield, UK) of
the resuspended cells and corresponding supernatants.
Percentage [125I]-MIBG cell uptake was calculated by
dividing the counts in the cell pellet by the total counts
(counts in cell pellet + counts in supernatant). All experi-
ments were performed in triplicates. The one-way
ANOVA and the Tukey’s HSD test were used to deter-
mine the significance of differences between mean values.In vivo bioluminescence and SPECT/CT imaging
All animal procedures were carried out in accordance
with the UK Animals (Scientific Procedures) 1986 Act
and institutional ethics regulation. SupT1/FLuc.2A.
RQR8.2A.hNET cells (5 × 106) or non-transduced SupT1
cells (5 × 106) were injected into the subcutaneous space
of the right flank of NOD/SCID mice (n = 3 in each
group). Seven days later, BLI images (Biospace photon
imager Optima system, Paris, France) were acquired 15
min post-intraperitoneal administration of 200 μL of D-
Luciferin (10 mg/mL) using a 50 mm CCD lens with a
sensitivity of 37 photons/s/sr/cm2. Images were analysed
using Biospace M3 Vision software. 15 MBq (150 μL) of
[123I]-MIBG (Mallinckrodt, Northampton, UK) was sub-
sequently administered to animals via tail vein followed
by whole body SPECT/CT imaging (nanoSPECT silver
upgrade, Mediso, Budapest, Hungary) at 1 h, 4 h and 24
h post injection. Images were reconstructed using HiS-
PECT software (InviCRO, Boston, USA) followed byimage processing and analysis using VivoQuant Software
(InviCRO, Boston, USA).
Results
ASP+-guided flow cytometry enables functional
assessment of hNET engineered cells
Functional determination of hNET vectors requires
costly and complex radiochemistry work. We hypothe-
sised that the fluorescent NET substrate ASP+ could
allow determination of hNET function based on flow cy-
tometry. A concentration and time-course titration assay
was designed to determine optimised conditions for effi-
cient cell staining and sorting of hNET expressing cells
using ASP+. hNET expressing and non-transduced
SupT1 cells were compared to quantify non-specific up-
take (Figure 1). Adequate discrimination between spe-
cific and non-specific ASP+ staining is essential to study
efficiency of hNET encoding vector transduction and re-
porter function and to facilitate isolation of pure hNET
positive cell populations. We determined that ASP+ is
both specifically and non-specifically taken up by cells
(Figure 1). We observed good discrimination of specific
and non-specific staining with a two-log shift in fluores-
cence. Optimal separation between hNET positive and
hNET negative cells, using minimum incubation time
and ASP+ concentration, was 30 min and 0.05 μM ASP+
(Figure 1).
Tricistronic pre-clinical vector for histochemistry, BLI and
SPECT tracking of engineered cells
We constructed a tricistronic vector which allows engi-
neered cells to be tracked in vivo by BLI and SPECT/
PET and ex vivo by histochemistry. We co-expressed a
bright red-shifted firefly luciferase, along with the hNET
and RQR8 - a small marker gene which binds the widely
used antibody QBEnd/10 enabling flow cytometry and
histochemistry. We used 2A peptide linkage to drive ob-
ligate stoichiometric co-expression [26]. Two candidate
tricistronic vector constructs were designed and tested;
one with 2A peptide linkage at the N-terminus of hNET
(FLuc.2A.RQR8.2A.hNET) and one at the C-terminus
(hNET.2A.FLuc.2A.RQR8). RQR8 function and trans-
duction efficiency of the two vectors was verified via
flow cytometry and QBEnd10 staining. As a reference,
SupT1 cells encoding an IRES linked bicistronic vector
(SupT1/hNET.I.CD34) were used. Using the optimal
staining conditions determined above, ASP+-guided
FACS was performed to isolate hNET positive SupT1
cells by gating on the brightest 5% of each population.
Post sorting, positive ASP+ staining increased from
59.4% to 99% ± 0.01% for SupT1/hNET.l.dCD34, 46.2%
to 93.6% ± 0.34% for SupT1/FLuc.2A.RQR8.2A.hNET,
and 52.4% to 93.6% ± 0.66% for SupT1/hNET.2A.
FLuc.2A.RQR8 (Figure 2). No difference in growth rates
Figure 1 ASP+ staining optimisation of hNET expressing cells. hNET positive (blue line) or non-transduced (red line) SupT1 cells were incubated
with increasing [ASP+] from 0 to 1 μM. For each concentration, FACS was performed at 10, 30, 60, 120 and 240 min. Suggested optimal concentration
and incubation time is 0.05 μM ASP+ and 30 min.
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transduced SupT1 control cells. hNET function in all cell
lines was tested over a period of 17 weeks via ASP+-guided
FACS without any significant reduction in uptake observed
(Additional file 1: Table S1).ASP+ screening to assess 2A peptide linkage orientation
and hNET function
Interestingly, using ASP+, we found that 2A orientation
within the tricistronic vector affected hNET function.
Sorted SupT1/FLuc.2A.RQR8.2A.hNET and SupT1/
hNET.2A.FLuc.2A.RQR8 cells were subject to ASP+-guided
flow cytometry with mean fluorescence intensities
measured as from the AUC. Despite resulting in a 1.7-fold
lower MFI compared to the bicistronic reference cells
(SupT1/hNET.l.dCD34), cells encoding the tricistronic
vector with 2A at the N-terminus of hNET (SupT1/
FLuc.2A.RQR8.2A.hNET) gave rise to a >4-fold higher
MFI (2292.33 ± 80.39 MFI) compared to cells encoding 2A
at the C-terminus of hNET (SupT1/hNET.2A.FLuc.2A.
RQR8) (549 ± 20.43 MFI) (Figure 3a). hNET function
in SupT1/FLuc.2A.RQR8.2A.hNET cells was furthercharacterised via radiosubstrate uptake assay. These cells
demonstrated >18-fold higher 125I-MIBG uptake (60.25% ±
1.34%) compared to non-hNET expressing control cells
(SupT1/NT) (3.18% ± 0.37%). Similar to ASP+ accumula-
tion profiles, 125I-MIBG uptake in SupT1/FLuc.2A.
RQR8.2A.hNET was 1.2-fold lower than in SupT1/hNET.l.
dCD34 cells, suggesting reduced hNET pumping capabil-
ities due to higher genetic load on tricistronic compared to
bicistronic vector.In vivo imaging of the tricistronic vector
As an initial in vivo validation of the hNET encoding
tricistronic bimodal imaging vector, 5 × 106 SupT1/
hNET.2A.FLuc.2A.RQR8 cells were inoculated into the
flanks of immunocompromised mice and imaged 7 days
later via BLI followed by SPECT/CT. Following lucif-
erin administration, bioluminescence was clearly visible
in the right flank (Figure 4a) (3.25 × 107 ± 9.11 × 102
CPM) indicating cell viability and FLuc function. Fol-
lowing intravenous tail vein injection of 123I-MIBG, dy-
namic whole body SPECT/CT images were collected at
30 min, 4 h and 24 h (Figure 4b,c,d,e). Consistent with
Figure 2 Tricistronic hNET vector design and ASP+-guided FACS. Three hNET encoding vectors were designed and transduced into SupT1 cells;
hNET.l.dCD34 (vector 1), SupT1/FLuc.2A.RQR8.2A.hNET (vector 2), SupT1/hNET.2A.FLuc.2A.RQR8 (vector 3). Transduced (grey lines) and non-transduced
(blue lines) cell populations were stained with ASP+ followed by flow cytometry (left column). ASP+-guided FACS was performed by gating on the
brightest 5% within each of the three cell populations (right column).
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favourable when imaging hNET cells with MIBG [21],
good signal-to-noise was observed at 24 h post radio-
tracer administration (Figure 4d,e). At the earlier time
points of 30 min and 4 h, renal clearance is observed
with high signal in the kidneys and bladder, with in-
creasing signal in the adrenals (high NET expressing
organ) (Figure 4b,c). Increasing signal was also ob-
served in the salivary and thyroid glands (sodium iodide
symporter expressing organs) due to tracer metabolism/
deiodination (Figure 4b,c,d,e). With decreased background
signal at 24 h, radiotracer accumulation in the sub-
cutaneous tumour can clearly be seen with regional
heterogeneity resolved. Percent injected dose (% ID) of
123I-MIBG in tumours at 24 h post injection, as deter-
mined by drawing image-guided 3D regions of interest,
was 3.12% ± 0.31% ID in hNET(+) xenografts, and
0.019% ± 0.01% ID in hNET(−) xenografts (equivalent
to background levels).Discussion
With the development of new cellular and gene therap-
ies, there is a need for non-invasive, readily available
methods for detecting and quantifying the fate of these
therapies in animal and man. As a translational ap-
proach, PET and SPECT genetic reporters have shown
promise and have supported numerous clinical trials
[27-29]. Various PET/SPECT reporter proteins have
been proposed including the human sodium iodide sym-
porter (hNIS), the hNET and the herpes simplex virus
thymidine kinase (HSVtk) [16,17,30,31]. Difficulties in
translating these into clinic include availability of clinic-
ally approved complementary radiotracers, early plan-
ning necessary to integrate the reporter protein and
imaging protocol into trial design, incorporation of the
reporter gene into the vector without exceeding the
packaging capacity or affecting cell function and limited
sensitivity in tissues with endogenous expression of the
reporter protein.
Figure 3 Fluorescence and radionuclide cell uptake studies. (a) ASP+-guided flow cytometry assessing hNET function in SupT1/NT (white), SupT1/
FLuc.2A.RQR8.2A.hNET (beige), SupT1/hNET.2A.FLuc.2A.RQR8 (light grey) and SupT1/hNET.l.dCD34 (dark grey) sorted cells. Mean fluorescence intensities
under the curves are presented. (b) hNET function in SupT1/hNET.2A.FLuc.2A.RQR8 cells was further characterised with an 125I-MIBG radiosubstrate
uptake assay. Percent uptake was determined for SupT1/NT (white), SupT1/hNET.2A.FLuc.2A.RQR8 (light grey) and SupT1/hNET.l.dCD34 (dark grey) cells
via gamma counting. Error bars are the mean ± SD for n = 3. Stats tests performed were ANOVA and Tukey’s HSD post hoc.
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strengths each modality (e.g. MRI, optical and nuclear)
has to offer, the use of multimodal multicistronic re-
porters is becoming increasingly popular [16]. For ex-
ample, co-expression of PET and BLI reporters would
enable rapid, affordable and sensitive BLI, alongside
complementary tomographic and quantitative PET
capabilities. Expression vectors are often composed of
multiple genes (e.g. a therapeutic, a marker gene, a
suicide gene and a reporter gene) some of which can
be large surface proteins, which may tax the vector
packaging capacity and transcriptional efficiency.
Strategies which promote maximising vector space are
therefore essential and may include gene and protein
truncation [22,32], efficient gene coupling approaches
[33,34] and the utility of dual purpose genes
[22,35,36].
Here, we have developed a trisictronic expression
vector containing a nuclear reporter (hNET), a BLI re-
porter (FLuc) and a highly compact dual-purpose
marker/suicide gene (RQR8). To achieve a compact
vector, genes were linked with the ‘self-cleaving’ small
2A peptide, driving obligate co-expression under a
single promoter (26). Exploiting the endogenousfluorescent properties of the hNET substrate ASP+, it
was possible to simultaneously, and efficiently, sort
pure cell populations and evaluate reporter function.
Such a system is unique to hNET as a nuclear reporter
and may circumvent the need for in vitro radioligand
cell uptake assays prior to in vivo use. Furthermore, as
hNET positive cells can be efficiently sorted using
ASP+-guided flow cytometry, hNET could double up
as a marker gene, leaving more flexibility to insert
other genes in the expression vector.
Using ASP+-guided flow cytometry, we demon-
strated that residual 2A amino acids attached to the
C-terminus of the transcribed hNET markedly re-
duced the protein capacity to accumulate substrate
into the cell. This finding further corroborates previ-
ous structure/function studies indicating the critical
contribution of the hNET C-terminus to transporter
trafficking, stability and function [37,38]. Conse-
quently, an expression vector with 2A cleavage site
upstream of hNET was taken forward for in vivo as-
sessment. FLuc/hNET cells were successfully visua-
lised using sequential BLI and SPECT imaging
demonstrating high target to background tumour visu-
alisation at 24 h post 123I-MIBG administration.
Figure 4 In vivo validation of the tricistronic vector hNET.2A.FLuc.2A.RQR8 via (a) BLI and (b-e) SPECT/CT. 5 × 106 SupT1/hNET.2A.FLuc.2A.
RQR8 were inoculated into the right flank of immunocompromised mice. Regions of interest were drawn around the right flanks and mean
luminescence signal intensity was measured (n = 3). (b-d) Maximum intensity projection (MIP) SPECT images and (e) SPECT/CT illustrate 123I-MIBG
clearance via renal excretion, with increasing signal in the adrenals, thyroid, salivary glands and tumour (d, e). Percent injected dose (n = 3) of
123I-MIBG within the tumours was determined by drawing 3D regions of interest. Colour bars represent counts per minute with maximum and
minimum threshold levels indicated.
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In conclusion, exploiting the unique fluorescent proper-
ties of ASP+, we have been able to explore hNET func-
tion in engineered cells. We have constructed a novel
pre-clinical tricistronic vector with BLI, SPECT, flow cy-
tometry and histochemical capabilities, which can be
widely applied in cell tracking studies supporting the de-
velopment of cell therapies. Further investigation with
regard to quantitatively correlating ASP+ and MIBG kin-
etics in hNET engineered cells, as well as determining
the in vivo sensitivity of the technique is required and
should be performed for each new cell line under
investigation.Additional file
Additional file 1: Table S1. Functional assessment of hNET cell lines over
time. SupT1 cells expressing hNET.l.dCD34 (vector 1), SupT1/FLuc.2A.
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